| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc9ddc40558152f16ef9180d14217782 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1676
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 |
| filingDate |
2014-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa47e79b9b7f5a9c7b4f59a435a1b57f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e91bba3b6ccbbf74266e2330c42823d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce218ca87d185b5cfe00f7a6efb0cd54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6671926247c06adcea3219f4a90ed5ec |
| publicationDate |
2018-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2673228-C2 |
| titleOfInvention |
Pharmaceutical composition comprising a solid dispersion of tadalafil |
| abstract |
FIELD: medicine; pharmaceuticals. n SUBSTANCE: present invention relates to a pharmaceutical composition comprising a tadalafil solid dispersion and at least two different types of polymers: at least one cationic methacrylate copolymer and at least one anionic copolymer of methacrylic acid. Cationic methacrylate copolymer is obtained based on dimethylaminoethyl methacrylate-butyl methacrylate-methyl methacrylate in a ratio of 2:1:1. Anionic copolymer of methacrylic acid is obtained based on a methacrylic acid-ethyl acrylate copolymer in a ratio of 1:1. Also described is a method for preparing a composition by wet granulation. Composition according to the invention exhibits a tadalafil dissolution rate of at least 85 wt% for 20 minutes when tested in 1,000 ml of phosphate buffer (pH 6.8) + 0.35 wt% sodium dodecyl sulphate (SDS) in a USP apparatus II (peak vessels) at 50 rpm. n EFFECT: disclosed is a pharmaceutical composition comprising a solid dispersion of tadalafil. n 20 cl, 2 dwg, 1 tbl, 1 ex |
| priorityDate |
2013-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |